drugset / Trial / NCT00864760
A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis under fasting conditions.
Timeline
- Start
- 1999-06
- Primary completion
- 1999-06
- Completion
- 1999-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gabapentin | Small molecule | 400 mg | — |
| Subject | Gabapentin | Small molecule | 800 mg | — |
Indications
No indication recorded.